🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A fantastic prospective report on H&N #reirradiation from the Tata Memorial group, one of the largest prospective H&N ReRT reports published. 📌 Patient selection = Crucial. Looking forward to detailed reporting of cumulative RT1 and RT2 dosimetry! sciencedirect.com/science/articl…

We are hiring for a talented Radiation Oncology Chair @UTHealthSAMDA - please let me know if I can provide any information about who we are looking for or help guide the application process . careers.astro.org/job/chair-of-t…

Translational research is a humbling privilege. I am continually inspired by patients who choose to give back by electing to participate in research. Patients and their families are indeed unsung heroes of biomedical innovation. Thank you! Herbert Irving Comprehensive Cancer Center #spinalab

Ablative radiation therapy effectively controlled tumors and provided favorable 2-year survival rates in patients with resectable pancreatic cancer who could not undergo surgery. ja.ma/4lxAyjx Eileen M O’Reilly John Cuaron

Fantastic read on The “Linear Non-Thinking Model” this morning! Excellent take by Susannah Ellsworth 🏆🎯 Well worth the brief read! #radonc open.substack.com/pub/radiatione…

Very useful prospective cohort study with excellent PRO data: ascopubs.org/doi/10.1200/OP… Thanks JCO Oncology Practice for the invitation to discuss palliative radiotherapy for incurable esophageal cancer: ascopubs.org/doi/10.1200/OP…

Great mid-week news on the publication front! Could it be that our GPC3-selective radiotheranostics agents aimed at #HCC could be repurposed for #NEPC? Fun collaboration with Adam Sowalsky, Misha Beltran and Peter Nelson (Fred Hutch Cancer Center)! Stay tuned! #radiopharmaceuticals

We’ve been running a prospective study of low-dose RT for osteoarthritis, so several people have sent this article to me. Question for people doing this in the US: Are you billing 3D (as this study seems to do)? What organs need to be spared 50cGy/fx? tinyurl.com/58kskxj2

Well done - Sounds like a great opportunity for a clinical study!

#ASCO25: In pts with 5–20 brain mets, Phase 3 trial shows SRS/SRT leads to significantly better QoL vs HA-WBRT (↓ symptoms & interference, p<0.001), with no OS difference (8.3 vs 8.5 mo). SRS/SRT should be new SoC in this setting. #radonc 🔗 meetings.asco.org/abstracts-pres…

Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial ⁦JAMA Surgery⁩ jamanetwork.com/journals/jamas…

🚨MATTERHORN🚨 🔎948 pts Stage II-IVa G/GEJ Adenocarcinoma Ph3 RCT: Peri-op FLOT +/- Durva Durva associated with: ✅⬆️EFS2 67% vs. 59%, p<0.001 ✅⬆️pCR 19% vs. 7% BUT 🚫🔺OS2 76% vs. 70%, p=NS Full pub here in NEJM : nejm.org/doi/full/10.10… #ASCO2025

Krishan Jethwa NEJM Unknown now is FLOT+IO vs Checkmate-577 and more specifically not even just IO for non-pCR but what about CRT+IO for all vs FLOT+IO? How can we build upon SANO foundation for patients who don’t want surgery also?

x.com/i/article/1929…

🚨ESOPEC, Patterns of Recurrence🚨 🔥DM is the predominant pattern of recurrence and a large driver of mortality (~30-50%) ⚠️Locoregional Recurrence Remains notable (~20%) 🧐 Wonder about combined (Chemo + CRT) 🧨 to build on D-FLOT or FLOT, ❓ with organ preservation #ASCO25

AI creating malware, self-editing its code, and attempting to blackmail engineers all to keep from being shut down (in controlled simulations). Most sobering read about AI thus far: tinyurl.com/3fy2ebmx